New York State Common Retirement Fund Purchases 178,981 Shares of BioNTech SE (NASDAQ:BNTX)

New York State Common Retirement Fund boosted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 457.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 218,067 shares of the company’s stock after buying an additional 178,981 shares during the period. New York State Common Retirement Fund owned approximately 0.09% of BioNTech worth $25,900,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in BNTX. Candriam S.C.A. grew its position in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after purchasing an additional 341,311 shares during the period. abrdn plc lifted its stake in BioNTech by 334.4% during the third quarter. abrdn plc now owns 225,992 shares of the company’s stock worth $26,841,000 after purchasing an additional 173,969 shares during the last quarter. SG Americas Securities LLC boosted its stake in BioNTech by 610.5% in the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after buying an additional 60,270 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in shares of BioNTech by 12.6% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock valued at $56,886,000 after purchasing an additional 53,800 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Price Performance

BNTX opened at $111.48 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The firm has a market cap of $26.51 billion, a P/E ratio of -49.33 and a beta of 0.26. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a 50-day moving average of $109.72 and a 200 day moving average of $95.84.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.86) EPS. On average, research analysts expect that BioNTech SE will post -2.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BNTX. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. HSBC lifted their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. HC Wainwright boosted their target price on shares of BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and raised their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, TD Cowen boosted their target price on shares of BioNTech from $85.00 to $132.00 and gave the stock a “hold” rating in a research report on Monday, October 21st. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, BioNTech has an average rating of “Moderate Buy” and an average target price of $135.54.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.